AMRN inventory positive factors as unbiased examine helps coronary heart illness remedy (NASDAQ:AMRN)

Industrial-stage biotech Amarin Company (NASDAQ:AMRN) gained ~13% Monday, the best intraday acquire since June, after the corporate stated that an unbiased examine supported the advantage of purified eicosapentaenoic acid (EPA), a element in its coronary heart illness remedy Vascepa/Vazkepa.

RESPECT-EPA trial funded by the Japanese Coronary heart Basis marginally achieved statistical significance with a 21.5% discount within the major composite endpoint associated to cardiovascular danger. It additionally indicated statistical significance for a 26.6% discount within the secondary composite endpoint.

Amarin (AMRN) stated that the RESPECT-EPA was the third examine to focus on the useful impression of purified EPA in reducing cardiovascular outcomes in sufferers with coronary artery illness.

The outcomes have been a part of a presentation on the American Coronary heart Affiliation (AHA) 2022. Different displays included in vitro knowledge supporting the antioxidant impact of EPA on low-density lipoprotein (LDL) in comparison with mineral oil.

Vascepa is a fish oil-derived remedy accredited within the U.S. for high-risk sufferers who proceed to undergo from cardiovascular danger after statin remedy.

Learn: In August, Amarin (AMRN) introduced new knowledge from its cardiovascular outcomes trial REDUCE-IT, which backed the FDA approval of the remedy in 2019.